Telo Genomics Announces Investor Relations Agreement and Option Grants | 2022-03-15 | Press Releases

0

Toronto, Ontario–(Newsfile Corp. – March 15, 2022) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” Where “TELO“) is pleased to announce that she has engaged Tracey Kidd (“Kidd“) to perform services related to investor relations activities for the Company, as defined in accordance with the policies of the TSX Venture Exchange (“TSXV“) and applicable securities laws.

Under the terms of a contract of engagement entered into with Kidd on March 15, 2022 (the “Assignment agreement“), Kidd will receive monthly cash compensation of $7,500 over a period of twelve months. The Company has granted Kidd 120,000 stock options, each option exercisable into one common share at an exercise price of 0.335 $ per share 30,000 options will vest three months from the date of the engagement agreement, and 30,000 options will vest on September 15and2022, December 15and2022 and March 15and2023. All vested options will be exercisable until the earlier of (i) 30 days after termination of the Agreement, and (ii) two years from the date of grant.

In addition, as part of the appointment of Dr. Ron McGlennen as a director of the Company, as previously announced on February 3, 2022, he was granted 250,000 options with a term of 5 years and an exercise price of $0.335 per common share pursuant to TELO’s approved stock option plan.

The stock option grants and the undertaking agreement are subject to the approval of the TSX Venture Exchange.

The securities described in this document have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or applicable exemption from regulatory requirements. ‘registration. This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be illegal prior to registration or qualification. under the securities laws of such province, state or jurisdiction.

About Telo Genomics

Telo Genomics is a biotechnology company pioneering the industry’s most comprehensive telomere platform with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of considerable interest to the medical community because it is less invasive and more easily reproducible than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative 3D telomere analysis with molecular biology and artificial intelligence to recognize genetic instability associated with disease, Telo Genomics develops simple and accurate products that improve daily care. patients by meeting the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been confirmed in over 150 peer-reviewed publications and 25 clinical studies involving over 3,000 patients with multiple cancers and Alzheimer’s disease. Our main application, Telo-MM, is being developed to provide important and actionable information to healthcare professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.

For more information, please contact:

Hugh Rogers,

Director

416-673-8487

[email protected]

MaRS Center, South Tower,

101 College Street, Suite 200,

Toronto, Ontario M5G 1L7

www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISTRIBUTION, PUBLISHING, DISTRIBUTING OR BROADCASTING DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR TO THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/116796

Share.

Comments are closed.